Table 1.
In vitro recognition of ALDH+ and ALDHbright cells present in human carcinoma cell lines, xenograft and surgically removed lesion by HLA-A2-restricted, ALDH1A188–96 peptide- CD8+ T cells in flow cytometry-based CMC assaysa.
| Cells | Cells only | Cells + ALDH1A1-specific CD8+ T cell + isotype mAb |
Cells + ALDH1A1-specific CD8+ T cells + KS1 mAb |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Cell number |
% ALDH+ |
% ALDHbright |
Cell number |
% ALDH+ |
% ALDHbright |
Cell number |
% ALDH+ |
% ALDHbright |
|
| PCI-13 | 380,000 | 17.6 | 3.2 | 302,000 (−22%) |
5.3 (−70%) |
0.5 (−83%) |
350,000 (−8%) |
13.6 (−23%) |
3.5 (+10%) |
| MDA-MB-231 | 204,000 | 28.3 | 0.4 | 188,000 (−8%) |
14.2 (−50%) |
0.3 (−75%) |
200,000 (−2%) |
31.1 (+11%) |
0.3 (−25%) |
| MIA PaCa-2 | 365,000 | 43.2 | 4.6 | 194,000 (−47%) |
37.2 (−14%) |
1.8 (−60%) |
299,000 (−18%) |
40 (−7%) |
3.8 (−18%) |
| PCI-13 xenograft | 350,000 | 13.1 | 2.1 | 213,000 (−29%) |
3.5 (−73%) |
0.6 (−72%) |
298,000 (−15%) |
13 (−5%) |
7-Jan (−22%) |
| SCCHN lesion 084124 | 150,000 | 3.4 | 0.9 | 100,000 (−33%) |
0.9 (−74%) |
0.1 (−89%) |
NDb | ND | ND |
Flow cytometry analyses of ALDH+ and ALDHbright cells present in SCCHN PCI-13, breast carcinoma MDA-MB-231 and pancreatic carcinoma MIA PaCa-2 cells, and digests of a PCI-13-derived xenograft and a SCCHN lesion following incubation with HLA-A2-restricted, ALDH1A188–96 peptide--specific CD8+ T cells at an E/T cell ratio of 2.5:1, followed by flow cytometry analysis with ALDEFLUOR±DEAB. 5×10 target cells were used with the exception of the analysis of the SCCHN lesion. Lysis was blocked by HLA-A2, A28-specific KS1 mAb. The percentages of ALDH+ and ALDHbright cells in each sample following incubation with HLA-A2-restricted, ALDH1A188–96 peptide-specific CD8+ T cells in the presence of isotype mAb or KS1 mAb are indicated. The decreases in these values compared to the “Cells only” control are indicated in parentheses
ND indicates not done due to insufficient cells